share_log

BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

Biolase(納斯達克：Biol)報道始於StockNews.com
Financial News Live ·  2022/12/05 15:11

Analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research report issued to clients and investors on Saturday. The brokerage set a "sell" rating on the medical technology company's stock.

斯托克新聞網的分析師在週六發佈給客户和投資者的一份研究報告中開始報道納斯達克(BIOLASE：BIOL-GET Rating)的股票。該經紀公司對這家醫療技術公司的股票設定了“賣出”評級。

A number of other brokerages have also recently weighed in on BIOL. Benchmark reduced their price target on shares of BIOLASE to $7.00 in a research report on Wednesday, November 16th. Maxim Group reduced their price target on shares of BIOLASE from $10.00 to $5.00 in a research report on Friday, November 11th. Finally, Ascendiant Capital Markets reduced their price target on shares of BIOLASE to $14.00 in a research report on Wednesday, November 16th.

其他一些券商最近也加入了Biol的行列。Benchmark在11月16日星期三的一份研究報告中將BIOLASE的股票目標價下調至7.00美元。Maxim Group在11月11日星期五的一份研究報告中將BIOLASE的股票目標價從10.00美元下調至5.00美元。最後，Ascaldiant Capital Markets在11月16日星期三的一份研究報告中將BIOLASE的股票目標價下調至14.00美元。

Get
到達
BIOLASE
生物酶
alerts:
警報：

BIOLASE Price Performance

Biolase價格表現

BIOL opened at $0.84 on Friday. The company has a fifty day moving average price of $1.83 and a two-hundred day moving average price of $3.41. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.27 and a current ratio of 2.46. BIOLASE has a 52 week low of $0.76 and a 52 week high of $13.83. The firm has a market capitalization of $6.00 million, a PE ratio of -0.24 and a beta of 1.34.

Biol上週五開盤報0.84美元。該公司的50日移動均線價格為1.83美元，200日移動均線價格為3.41美元。該公司的負債權益比率為0.92，速動比率為1.27，流動比率為2.46。Biolase的52周低點為0.76美元，52周高位為13.83美元。該公司市值為600萬美元，市盈率為-0.24，貝塔係數為1.34。

Institutional Investors Weigh In On BIOLASE

機構投資者看好BIOLASE

Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC bought a new stake in BIOLASE in the 2nd quarter valued at $118,000. Capital Wealth Alliance LLC bought a new stake in BIOLASE in the 2nd quarter valued at $51,000. Commonwealth Equity Services LLC lifted its position in BIOLASE by 117.8% during the 1st quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock worth $35,000 after buying an additional 54,650 shares in the last quarter. Essex Investment Management Co. LLC lifted its position in BIOLASE by 62.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 105,318 shares of the medical technology company's stock worth $256,000 after buying an additional 40,440 shares in the last quarter. Finally, Perkins Capital Management Inc. lifted its position in BIOLASE by 11.6% during the 3rd quarter. Perkins Capital Management Inc. now owns 132,070 shares of the medical technology company's stock worth $321,000 after buying an additional 13,770 shares in the last quarter. 21.21% of the stock is owned by institutional investors.
機構投資者最近增持或減持了該股。Citadel Advisors LLC在第二季度購買了BIOLASE的新股份，價值11.8萬美元。資本財富聯盟有限責任公司在第二季度購買了BIOLASE的新股份，價值51,000美元。聯邦股票服務有限責任公司在第一季度將其在BIOLASE的頭寸提高了117.8%。Federal Equity Services LLC現在持有這家醫療技術公司101,046股股票，價值35,000美元，上個季度又購買了54,650股。埃塞克斯投資管理公司第三季度將其在BIOLASE的頭寸提高了62.3%。Essex Investment Management Co.LLC現在持有這家醫療技術公司105,318股股票，價值25.6萬美元，上個季度又購買了40,440股。最後，珀金斯資本管理公司(Perkins Capital Management Inc.)在第三季度將其在BIOLASE的頭寸提高了11.6%。珀金斯資本管理公司(Perkins Capital Management Inc.)現在持有這家醫療技術公司132,070股股票，價值321,000美元，上個季度又購買了13,770股。21.21%的股份由機構投資者持有。

BIOLASE Company Profile

Biolase公司簡介

(Get Rating)

(獲取評級)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Biolase公司與其子公司一起，在美國和國際上為牙科醫生及其患者開發、製造、營銷和銷售激光系統。它的牙科激光系統允許牙醫、牙周病醫生、牙髓醫生、口腔外科醫生和其他牙科專家執行一系列微創牙科手術，如美容、修復和複雜的外科應用。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
  • Intel is a Sleeping Giant Ready to Awaken
  • Why CSL Ltd Stock Could Be Worth a Look
  • MarketBeat: Week in Review 11/28 – 12/02
  • Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
  • Institutions Are Buying Ambarella, Should You?
  • 免費獲取StockNews.com關於BIOLASE的研究報告(Biol)
  • 英特爾是一個沉睡的巨人，準備醒來
  • 為什麼CSL有限公司的股票值得一看
  • MarketBeat：回顧一週11/28-12/02
  • Okta Inc.慶祝收益節節攀升，但他們能持續這種提振嗎？
  • 機構正在購買安巴雷拉，你應該嗎？

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.

接受《BIOLASE日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BIOLASE和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論